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Abstract: Patients infected with the human immunodeficiency virus (HIV) have an increased 
cardiovascular risk. Although initially this increased risk was attributed to metabolic alterations 
associated with antiretroviral treatment, in recent years, the attention has been focused on the HIV 
disease itself. Inflammation, immune system activation, and endothelial dysfunction facilitated 
by HIV infection have been identified as key factors in the development and progression of 
atherosclerosis. In this review, we describe the epidemiology and pathogenesis of cardiovascular 
disease in patients with HIV infection and summarize the latest knowledge on the relationship 
between traditional and novel inflammatory, immune activation, and endothelial dysfunction 
biomarkers on the cardiovascular risk associated with HIV infection.
Keywords: HIV, cardiovascular disease, immune activation, inflammation, antiretroviral 
therapy
Importance of cardiovascular disease in patients 
infected with the human immunodeficiency virus
In regions with universal access to care and antiretroviral therapy (ART), the progno-
sis of patients infected with the human immunodeficiency virus (HIV) has improved 
substantially.1–4 In the last 2 decades, the incidence and mortality of acquired immu-
nodeficiency syndrome (AIDS)-defining illnesses (associated with severe immunosup-
pression in advanced stages of HIV infection) have been dramatically reduced, whereas 
the role of non-AIDS comorbidities has risen.5,6 A marked decrease in overall mortality 
due to AIDS-defining causes has been observed, while the proportion of deaths from 
other causes has increased, including those caused by cardiovascular disease (CVD).6–9 
Similarly, hospitalizations due to AIDS-defining illnesses have decreased in European 
and North American populations, while admissions for non-AIDS diseases and CVD 
have increased.10,11
Patients with HIV infection have higher atherosclerotic CVD rates than the general 
population.12 HIV patients experience more clinical cardiovascular events (coronary 
heart disease13–15 and peripheral artery disease),16 and subclinical cardiovascular damage 
(elevation of intima–media thickness [IMT],17 coronary calcification,18 abnormal ankle–
brachial index,19 silent myocardial ischemia,20 or endothelial dysfunction).21 In addition, 
the incidence of ischemic stroke in the HIV-infected population is considerably high, 
particularly in young adults, although no studies have determined whether stroke risk 
is greater in this population.22,23
Besides atherosclerotic coronary heart disease, other cardiac abnormalities have 
been associated with HIV infection.24 Thus, in the pre-ART era, a high incidence of 
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dilated cardiomyopathy with left ventricular dysfunction 
related to viral myocarditis was reported, mainly during 
the AIDS stage.24 More recent studies, in settings with 
unrestricted access to ART, reported a low prevalence of 
dilated cardiomyopathy, but a high burden of subclinical 
myocardial disease (cardiac steatosis, myocardial fibrosis, and 
alterations in cardiac  function) in HIV patients as compared 
to uninfected controls.25 Moreover, HIV patients may be at 
an increased risk of sudden arrhythmic death. The prevalence 
of prolonged corrected QT, a major risk for polymorphous 
ventricular tachycardia (Torsades de pointes) and sudden 
arrhythmic death, is also increased in HIV patients.26 In this 
regard, sudden cardiac death rate (due to atherosclerotic and/or 
arrhythmic causes) is 4.5-fold higher in HIV-infected patients 
than among those observed in the general population.27
On the other hand, the mean age of the HIV population 
is increasing due to the effectiveness of ART and increased 
life expectancy, favoring the development of age-associated 
comorbidities, many of which are related to CVD, such as 
type 2 diabetes mellitus (T2DM), hypertension (HT), and 
chronic kidney disease (CKD). In the Swiss HIV Cohort 
Study,28 which gathered patient data from 1990–2010, the 
proportion of patients older than 50 years increased from 
less than 5% to just over 30%. It is expected that if this trend 
continues, in the next decade, 50% of patients in this cohort 
will be above 50 years.
In addition to chronological aging, it is believed that 
HIV patients experience accelerated biological aging, 
thus contributing to the early development of age-related 
comorbidities.29–31 Patients with HIV infection have a higher 
prevalence of noninfectious comorbidities commonly seen in 
the elderly (T2DM, CVD, osteoporosis, and CKD).32–35 An 
interesting case-control study in an Italian population found 
a prevalence of comorbidity in HIV patients equivalent to 
that observed in control individuals 10–15 years older.32 
As seen in these studies, we are witnessing a change in the 
patterns of morbidity and mortality among the HIV-infected 
population, leading researchers to shift the focus to non-AIDS 
comorbidity, where CVD plays a central role.
Etiopathogenesis of cardiovascular 
disease in patients with HIV 
infection
The higher cardiovascular risk observed in patients with HIV 
infection is due to a combination of several determinants, 
including factors related to antiretroviral treatment, the inher-
ent impact of the infection, a high prevalence of traditional 
cardiovascular risk factors among HIV-infected individuals, 
and the presence of other factors that occur more frequently 
in these patients: coinfection with hepatitis C virus (HCV), 
coinfection and the replication of herpes family viruses, or 
the development of CKD (Figure 1).
Antiretroviral drugs
Initially, the elevated cardiovascular risk observed in HIV 
patients was attributed to metabolic alterations associated with 
ART, due particularly to the effect of viral protease inhibi-
tors (PI), whose introduction into clinical practice coincided 
with the first reported cases of ischemic heart disease in HIV 
patients.36,37 This relationship between CVD and ART was 
subsequently confirmed in epidemiological studies.12 The most 
representative study, the Data Collection on Adverse Events of 
Anti-HIV Drugs Study (DAD Study),38 showed a significant 
increase in acute myocardial infarction (AMI) incidence upon 
exposure to ART, with an increased AMI risk of 26% after 
6 years of treatment. The increased cardiovascular risk asso-
ciated with ART has been attributed to deleterious metabolic 
effects of these drugs, which favor the development of hyper-
cholesterolemia and hypertriglyceridemia, insulin resistance, 
and T2DM.39 These alterations may occur either independently 
or as part of other disorders, such as metabolic syndrome or 
lipodystrophy. To a greater or lesser extent, the appearance 
of these entities has been reported in patients treated with 
PI drugs, nucleoside/nucleotide analog reverse transcriptase 
inhibitors (NRTIs) and non-nucleoside/ nucleotide reverse 
transcriptase inhibitors. These alterations depend on the type 
of drug administered, and drugs belonging to the same family 
may have different effects. While these adverse effects have 
decreased with the new generation of antiretroviral drugs,40 the 
initiation of ART is usually associated with increased plasma 
lipids (triglycerides and total cholesterol with elevations in 
low-density lipoprotein [LDL] cholesterol [LDL-C] and, to a 
lesser extent, high-density lipoprotein cholesterol [HDL-C]) 
which, in part, could also be related to the weight gain observed 
after starting ART.41
In addition to these metabolic effects, the use of some 
antiretroviral drugs may induce other proatherogenic effects. 
Studies conducted in vitro and in healthy volunteers have 
revealed that some antiretrovirals – mainly PIs, but also 
NRTIs – could impair endothelial function, and increase 
oxidative stress and inflammation, inducing the early onset of 
senescence markers in endothelial and mononuclear cells.42–45 
However, the data of many clinical studies suggest that ART 
dampens inflammation, immune activation and endothelial 
dysfunction in HIV-infected patients, probably through the 
suppression of HIV replication, as we further discuss.
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Figure 1 Determining factors of CVD in HIV-infected individuals.
Notes: In addition to lifestyle and individual predisposition, HIV-infected patients present other factors that determine CVD. HIV itself determines a state of persistent 
inflammation and immune activation, metabolic abnormalities, and vascular dysfunction. On the other hand, although some antiretroviral drugs may be associated with some 
deleterious alterations, ART has a positive net impact on inflammation, immune activation, and endothelial dysfunction that overcomes the possible deleterious effects 
associated with some drugs (note that the green lines are thicker than the orange ones). Finally, patients with HIV infection are frequently coinfected with HCV, CMV, or 
herpes viruses that may contribute to CVD by promoting chronic inflammation and immune activation.
Abbreviations: HIV, human immunodeficiency virus; ART, antiretroviral therapy; CVD, cardiovascular disease; HCV, hepatitis C virus; CMV, cytomegalovirus.
HIV infection
In recent years, the ART-dependent atherosclerosis hypoth-
esis has been challenged. Evidence from experimental and 
observational studies, especially the findings of the  Strategies 
for Management of Anti-Retroviral Therapy Study (SMART 
Study),46 have redirected attention from ART to the conse-
quences of HIV infection itself. In this study, two different 
therapeutic strategies were compared. In the first group, ART 
was interrupted when a recovery of the immune system was 
achieved and CD4+ lymphocytes were above 350 cells/mL, 
whereas in the second group, ART was maintained con-
tinuously, regardless of CD4+ levels. Patients in whom the 
treatment was discontinued showed increased complications 
associated with immunosuppression and an increased risk of 
all-cause mortality. Moreover, patients assigned to discon-
tinuous therapy exhibited an unexpected increase in cardio-
vascular outcomes in spite of less exposure to antiretroviral 
drugs.46 These results suggested that uncontrolled HIV infec-
tion might have a greater influence on CVD than ART.
HIV infection may increase cardiovascular risk by sev-
eral mechanisms: 1) persistent inflammation and immune 
activation; 2) endothelial damage; 3) increased thrombotic 
activity; 4) higher oxidative stress; and 5) indirect metabolic 
disorders. HIV infection leads to the activation of several 
inflammatory pathways, causing the release of cytokines 
and endothelial adhesion molecule expression that facili-
tate adhesion and the transmigration of leukocytes.47 There 
is a close relationship between endothelial dysfunction 
and inflammation/immune activation. Various cytokines 
induce endothelial activation and alter its functionality.48 
 Additionally, HIV produces direct endothelial cell damage, 
increasing endothelial permeability, favoring apoptosis and 
increasing the expression of adhesion molecules (E-selectin, 
VCAM-1, and ICAM-1).49–54
HIV infection is also accompanied by immune activation, 
as determined by the elevation of several activation markers 
on monocytes/macrophages (sCD163, sCD14, and CD14+/
CD16+ monocyte expansion) and the increased proportion 
of activated CD8 T-lymphocytes human leukocyte antigen 
(HLA)-DR+CD38+.55–60 Monocytes/macrophages play a 
central role in the genesis and development of  atherosclerosis. 
Thus, in atherosclerotic plaques, macrophages phagocyte 
modified lipoproteins, promote proinflammatory and chemot-
actic cytokine secretion, and mediate cholesterol efflux from 
the arterial wall.61 HIV infection increases the proportion 
of CD14+/CD16+ monocytes, as it exhibits an activated 
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phenotype with increased secretion of proinflammatory 
cytokines.58,59 Furthermore, HIV blocks the adenosine 
triphosphate-binding cassette transporter A1 (ABCA-1) 
pathway, suppressing reverse cholesterol transport from 
arterial wall macrophages to HDL particles, and favoring the 
accumulation of foam macrophages within atherosclerotic 
plaques.62
Inflammation and immune activation are also associated 
with increased thrombotic activity, with the elevation of 
biomarkers such as D-dimer (a fibrin degradation product 
that may be elevated in response to inflammatory stimuli 
and bacterial translocation), von Willebrand factor, and 
fibrinogen.63
HIV also induces oxidative stress, impairing the mecha-
nisms of DNA repair and promoting the accumulation of 
oxidative lesions.64 Furthermore, HIV promotes atherogen-
esis through its metabolic effects, mainly decreasing HDL-C 
and apoA1, decreasing LDL particle clearance, as well as 
increasing triglycerides and very LDL-C. This pattern is 
associated with a high prevalence of proatherogenic small and 
dense LDL particles.65–67 It has been proposed that circulating 
HDL particles in different proinflammatory conditions are 
functionally less active and are therefore less atheroprotec-
tive, reducing their ability to perform cholesterol efflux.68 
However, this scenario has not been explored specifically 
in HIV infection.
Inflammation, immune activation, and prothrombotic 
state driven by HIV infection may participate not only in 
primary atherosclerosis, but also in occlusive complica-
tions after arterial revascularization procedures. It has been 
reported that HIV patients may have higher rates of stent 
restenosis and stent thrombosis after percutaneous coronary 
intervention.69–71 However, the results are not homogeneous 
and some studies report no differences in revascularization 
rates or major cardiac events after percutaneous coronary 
intervention in HIV-positive patients compared to age- and 
sex-matched HIV-negative subjects.72,73
Traditional cardiovascular risk factors
HIV patients show a high prevalence of certain traditional 
cardiovascular risk factors, such as smoking, dyslipidemia, 
and T2DM.12,74–76 The importance of these cardiovascu-
lar risk factors has been demonstrated in several cohort 
studies, highlighting a strong association between HIV 
and CVD, one that is even stronger than the link between 
ART and CVD. However, it is important to note that both 
ART and HIV infection may also induce dyslipidemia and 
diabetes.
Lifestyle
Smoking is very common in HIV patients, more so than in the 
general population; between 35% and 72% of HIV-infected 
individuals smoke depending on the population analyzed.77–81 
Dietary habits also appear to be worse in HIV patients. In a 
case-control study that included 356 HIV-infected patients 
and 162 healthy volunteers, it was found that infected patients 
had significantly higher trans-, saturated-, and total fat and 
cholesterol consumption.82 One potential explanation for 
this difference is that without appropriate dietary control, 
many HIV patients have a greater caloric intake in order to 
compensate for lipoatrophy. Interestingly, in HIV patients that 
started ART, the incidence of dyslipidemia was significantly 
lower in those subjects who initiated a hypocaloric and low 
saturated fat diet as compared with patients who did not 
undergo a dietary intervention.41
Metabolic cardiovascular risk factors
Patients with HIV infection share the same predisposing factors 
for the development of dyslipidemia, diabetes, or metabolic 
syndrome as the general population.74 However, in these indi-
viduals, other factors coexist such as the HIV infection itself, 
ART, and/or HCV coinfection, which could explain the higher 
prevalence of abnormal carbohydrate and lipid metabolism 
observed in this population. In the DAD study,76 the prevalence 
of dyslipidemia at baseline was 45.9%. It is expected that this 
prevalence would decrease with the use of lipid-lowering and 
antiretroviral drugs with a better metabolic profile. However, 
recent data from the Spanish cohort CoRIS81 showed that the 
prevalence remained elevated, as 27% of patients exhibited 
hypercholesterolemia, 36% low HDL cholesterol, and 19% 
hypertriglyceridemia. The frequency of abnormal carbohydrate 
metabolism has decreased in recent years, revealing a pres-
ence of diabetes of 17% in older cohorts,76 although a recent 
analysis found only 2.9% of the cohort to be diabetic.81 Patients 
with HIV infection also have a high prevalence of metabolic 
syndrome, around 25%.81,83,84
Hypertension
The prevalence of HT in patients with HIV infection does not 
appear to be greater than in non-HIV individuals.73 A recent 
meta-analysis showed lower levels of systolic and diastolic 
blood pressure in HIV-infected patients compared to HIV-
negative individuals.85 Interestingly, it has been hypothesized 
that in spite of normal brachial blood pressure, HIV patients 
may have higher arterial stiffness than healthy controls,86,87 
emerging as an early marker of vascular damage related to 
HT; however, the data remain conflicting.88
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Additional factors
In addition to the HIV infection itself, other factors may be 
involved in the increased vascular risk in patients with HIV 
infection, such as the presence of chronic coinfections (HCV 
or herpes family viruses) and CKD.40 HCV infection pro-
motes inflammation, platelet activation, endothelial dysfunc-
tion, and increased production of reactive oxygen species.89 
In the general population, HCV infection has been associated 
with a higher prevalence of subclinical atherosclerosis90–92 and 
overt CVD.93–95 Similarly, in HIV patients, HCV coinfection 
has been associated with a higher frequency of atheroscle-
rotic plaques (carotid or femoral),96 stroke, and AMI when 
compared to non-HCV coinfected patients.97,98
Latent infection with a virus of the herpes family has 
atherogenic effects99 and is associated with subclinical ath-
erosclerosis.100,101 It has been hypothesized that herpes viruses 
may have more serious cardiovascular effects in HIV-infected 
patients, contributing to immune activation and inflamma-
tion. Cytomegalovirus (CMV) infection has been associated 
with atherosclerosis in HIV-infected patients. CMV-specific 
T-cell responses and CMV immunoglobulin G levels have 
been associated with increased carotid atherosclerosis.102,103 
Moreover, other herpes viruses have been implicated. 
A case-control study that evaluated the association between 
subclinical coronary atherosclerosis and markers of CMV, 
herpes simplex virus 1 and 2, and human herpes virus type 
8 in HIV patients, showed that herpes simplex virus 2 was 
independently associated with the presence of subclinical 
coronary atherosclerosis, supporting the proatherogenic role 
of the herpes virus in this population.104
Finally, CKD is more frequent in HIV patients, and this 
factor is widely associated with CVD.105 This higher preva-
lence of renal disease can be explained by several factors, 
including a direct effect of HIV, the potential nephrotoxicity 
of some antiretroviral agents, the presence of traditional 
cardiovascular risk factors such as diabetes, and the develop-
ment of atherosclerosis, which is bidirectionally associated 
with CKD.106 It is important to note that although some 
antiretroviral drugs may cause renal toxicity, many studies 
have shown that ART slows the decline of the estimated 
glomerular filtration rate, probably related to the effect of 
HIV viral suppression on glomerular function.107–109
Inflammation, immune activation,  
and endothelial dysfunction  
in patients with HIV infection
Multiple biomarkers of inflammation, immune activation, and 
endothelial dysfunction associated with CVD in the general 
population have been studied in HIV patients (Table 1). 
Numerous inflammatory mediators and adhesion molecules 
are elevated in the HIV population, including high-sensitive 
C-reactive protein (hsCRP), interleukin (IL)-6, soluble recep-
tors of tumor necrosis factor (sTNFR), soluble vascular cell 
adhesion molecule-1 (sVCAM-1), soluble intercellular adhe-
sion molecule-1 (sICAM-1), or asymmetric dimethylarginine 
(ADMA).110–114 Some of these biomarkers have been associ-
ated with the presence of subclinical vascular disease and/or 
cardiovascular events in HIV-infected patients. Thus, hsCRP 
predicts the risk of CVD and all-cause mortality in the HIV 
population.115,116 High levels of IL-6 are also associated with 
an increased risk of death from any cause and cardiovascular 
events.116–118 Moreover, sTNFR has been associated with non-
AIDS-defining morbid events during ART, including CVD.119 
In HIV patients, the levels of sVCAM-1 have been associated 
with carotid IMT and carotid plaques,120,121 whereas ADMA 
levels have been related with coronary calcium score, all of 
which are surrogate markers of atherosclerosis.122
Immune activation markers are also elevated in the HIV 
population. Soluble markers such as sCD163 and sCD14, and 
the proportion of activated subsets of monocytes (CD14+/
CD16+) and CD8 T-cells (HLA-DR+CD38+), are increased 
in HIV patients.56–60,123,124 Our group has recently reported 
that HIV patients also have lower levels of soluble tumor 
necrosis factor-like weak inducer of apoptosis (sTWEAK), 
a multifunctional cytokine involved in various atherogenic 
processes through its interaction with Fn14 and CD163.124 
sCD163 levels have been associated with the presence of 
subclinical atherosclerosis in patients with HIV infection. In 
102 young HIV-infected men who were asymptomatic and 
had a low or undetectable viral load, sCD163 levels were 
independently associated with the percentage of noncalci-
fied coronary plaques in both the overall analysis and in the 
69 patients with undetectable viral RNA.125 These results 
were replicated in a study with 60 HIV-infected women that 
showed higher levels of sCD163 in those with noncalcified 
coronary plaques.126 Furthermore, in a similar scenario, 
sCD163 levels correlated positively with inflammation, as 
measured by aortic positron emission tomography.127 In both 
cases, neither the presence of coronary plaques nor vascu-
lar inflammation was associated with other biomarkers of 
CVD, such as hsCRP or D-dimer. sCD14 levels and CD14+/
CD16+ monocytes have also been associated with coro-
nary artery calcium score.128,129 These results suggest that 
monocyte–macrophage activation could play a central role 
in both coronary and aortic atherosclerosis in HIV patients 
on effective ART, independently of classical inflammatory 
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Table 1 Biomarkers of inflammation, immune activation, and endothelial dysfunction associated with CVD in the general population 
and performance in HIV-infected patients
Association with CVD  
in non-HIV patients
Effect of  
HIV*
Effect of  
ART**
Association with CVD in HIV-infected 
patients
Inflammation
hsCRP ↑↑ in CVD patients and predicts  
incident CVD164–167
↑↑110 ↓↓124,130 CVD115,116 (not seen in Ford et al168)
IL-6 ↑↑ in CVD patients and predicts  
incident CVD169–172
↑↑110 ↓↓131 CVD116–118
sTNFR ↑↑ in LVH173 
Predicts HF in CAD174–176
↑↑113,124 ↓↓124,131 Subclinical atherosclerosis (IMT)113,120 
CVD119
Monocyte activation
sCD163 ↑↑ in CAD, PAD, subclinical  
atherosclerosis177–179
↑↑58,59,123,124 ↓↓123,124 Subclinical atherosclerosis (CoP)125,126 
(not seen for IMT in Longenecker et al120) 
No prediction of first AMI180,a
sCD14 Associated with subclinical  
atherosclerosis and incident CVD181
↑↑58–60 →137,138← Subclinical atherosclerosis (CAC,
128 iMT182) 
(not seen for IMT in Longenecker et al120)
CD14+/CD16+ expansion Associated with incident  
CVD183–185 (not seen in Jaipersad  
et al186 and Berg et al187) 
↑↑58,59 ↓↓123,136,b Subclinical atherosclerosis (CAC)129 
(no association with IMT in Barbour et al188)
Endothelial disturbances
sVCAM-1 ↑↑ in CVD patients and predicts  
incident CVD189,190
↑↑111–113 ↓↓130–133 Subclinical atherosclerosis (IMT, CaP120,121) 
(not seen in Hileman et al191)
sICAM-1 ↑↑ in CVD patients and predicts  
incident CVD165,189–190
↑↑111–113 ↓↓130–133 No association with IMT in Hileman et al191
ADMA ↑↑ in CVD patients and predicts  
incident CVD192,193
↑↑114,124 ↓↓134,135 
(not seen in  
Beltrán et al124)
Subclinical atherosclerosis (CAC122) 
PAH194
sTweAK ↓↓ in CVD patients179,195,196
Low levels predict CV outcomes in  
PAD, HF, and CKD patients197–199
↓↓124 →124← Not known
Notes: *Comparison of HIV-infected patients versus non-HIV-infected controls. **Comparison of HIV-infected patients prior to and after initiating ART. aNested case-
control study. bHIV-infected patients receiving ART presented with a lower proportion of CD16+ monocytes; no comparison prior to versus after ART.
Abbreviations: CVD, cardiovascular disease; HIV, human immunodeficiency virus; hsCRP, high sensitivity C-reactive protein; IL, interleukin; sTNFR, soluble receptors of 
tumor necrosis factor; LVH, left ventricular hypertrophy; HF, heart failure; IMT, intima–media thickness; CAD, coronary artery disease; PAD, peripheral artery disease; CoP, 
coronary plaques; AMI, acute myocardial infarction; CAC, coronary artery calcium; sVCAM-1, soluble vascular cell adhesion molecule-1; CaP, carotid plaques; sICAM-1, 
soluble intercellular adhesion molecule-1; ADMA, asymmetric dimethylarginine; PAH, pulmonary arterial hypertension; sTWEAK, soluble tumor necrosis factor-like weak 
inducer of apoptosis; CV, cardiovascular; CKD, chronic kidney disease; ART, antiretroviral therapy.
biomarkers. In apparent contrast to these results, a study 
of 60 HIV-infected patients receiving ART with controlled 
viral replication found no association between carotid IMT 
and plaques with sCD14, sCD163, or proinflammatory 
monocyte subsets. However, the IMT was correlated with 
concentrations of fibrinogen and sTNFR-I, and subjects 
with carotid plaques had higher levels of sVCAM-1 and 
a higher percentage of CD38+HLA-DR+ CD8 T-cells.120 
These results are not necessarily contradictory and may 
reflect the specific role of different immune responses in 
the genesis of different atherosclerotic lesions. Supporting 
this hypothesis, it has been recently reported that in HIV-
treated patients, sCD14 was independently associated with 
coronary artery calcium, while T-cell activation and sys-
temic inflammation biomarkers, but not sCD14, correlated 
with carotid IMT.128 To clarify this issue, more studies are 
needed to assess the relationship of these biomarkers with 
the incidence of different atherosclerotic lesions in different 
vascular territories.
Role of ART in the control 
of inflammation, endothelial 
dysfunction, and immune activation
Contrary to the initial perception, a number of data support 
the notion that ART has a net protective effect on CVD in 
HIV patients.46 It is hypothesized that this effect is mediated 
by ART’s ability to reduce inflammation, immune activation, 
and endothelial dysfunction by suppressing HIV replication 
(Table 1).
It has been reported that ART reduces inflammation 
and endothelial dysfunction biomarkers.130–135 A decrease 
in sVCAM-1, sICAM-1 and hsCRP was observed in 115 
HIV-infected patients after 2 months and 14 months of 
antiretroviral treatment.117 In a further study, sTNFR-I, 
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sTNFR-II, sVCAM-1, sICAM-1, and IL-6 plasma levels were 
significantly decreased after 24 weeks and 96 weeks of ART.131 
Additionally, ADMA levels also seem to be reduced after suc-
cessful ART with suppression of viral replication.134,135
A number of studies have also shown that immune activa-
tion decreases after ART. Data from two case-control studies 
suggest that sCD163 plasma levels decrease after ART.123,124 
Moreover, ART-treated patients have a lower proportion of 
proinflammatory CD14+/CD16+ monocytes than patients 
who never received ART or those who discontinued this 
therapy.123,136 However, a reduction of sCD14 levels with ART 
has not been observed with similar concentrations before and 
after receiving treatment.137,138
It is important to note that even in individuals with spon-
taneously suppressed viremia, the so-called “controllers”, 
ART reduced immune activation markers, specifically T-cell 
activation, and provoked a higher reduction of viremia.139 
These patients showed higher subclinical CVD burden 
(coronary plaques or increased carotid IMT) than healthy 
individuals, in spite of maintaining suppressed viremia.140,141 
Pereyra et al141 showed that controller HIV patients had a 
similar coronary disease burden as HIV patients on ART who 
exhibited suppressed viremia. In the study, controller HIV 
patients showed higher levels of sCD163, but no significant 
differences were observed in hsCRP plasma levels.141 These 
data support the key role of monocytes/macrophages in 
HIV-associated coronary atherosclerosis and the importance 
of ART in the reduction of activation of these cells, even in 
low viral replication situations.
However, it is important to note that ART did not com-
pletely reverse inflammation, immune activation, and endothe-
lial dysfunction in HIV patients. In a study involving 781 
patients from the SMART study and 8,500 HIV- seronegative 
control subjects from two large  population-based studies 
(Multi-Ethnic Study of Atherosclerosis [MESA] study and 
Coronary Artery Development in Young Adults [CARDIA] 
study), the HIV patients had higher concentrations of hsCRP, 
IL-6, D-dimer, and C cystatin as compared with uninfected 
subjects, even when viral replication was suppressed with 
ART.110 Similar results were observed in a small case-control 
study, where ART reduced the concentrations of sVCAM-1, 
hsCRP, and sTNFR-II, although they remained elevated when 
compared with healthy subjects in spite of viral suppres-
sion.124 Also, sCD163 plasma levels decreased with ART but 
remained elevated as compared to healthy controls.123,124
Altogether, these results support the claim that ART 
reduces immune activation, inflammation, and endothe-
lial activation, explaining the favorable net effect on 
cardiovascular risk, in spite of the deleterious metabolic 
effects. Therefore, ART is a key factor in preventing CVD in 
patients with HIV. However, in spite of ART, these patients 
maintain a persistent state of immune activation, inflamma-
tion, and endothelial activation that could justify the increased 
frequency of CVD observed in HIV patients, even with stable 
suppression of viral replication.
Factors potentially involved in 
persistent inflammation and 
immune activation in HIV patients
Several factors could explain the persistent state of immune 
activation, inflammation, and endothelial activation in spite of 
the suppression of viral replication after ART (Figure 2).
Homeostatic drive and time  
to ART initiation
Sustained viral replication may promote an immune/ 
inflammatory response that cannot be reversed after a certain 
point. Therefore, starting ART before reaching this immune/
inflammatory set point may prevent the state of persistent 
inflammation and immune activation. Supporting this 
hypothesis, the results of several studies have demonstrated 
that starting ART with low CD4 counts and/or a lowest CD4 
nadir was associated with worse immunologic outcomes, 
even if patients achieved effective viral suppression.142–144 
Treating HIV infection in the acute phase significantly 
reduces the proportion of activated CD38+HLA-DR+ 
CD8 T-cells when compared to nontreated patients.145,146 
In the Options Project,147 patients who started ART in the 
first 6 months after infection had a lower proportion of 
activated CD8 T-cells than those who initiated treatment 
2 years or more after the infection. In another interesting 
study, Burdo et al123 showed that patients with chronic HIV 
infection experienced a decrease of sCD163 levels after 3 
months of ART; however, the sCD163 plasma concentration 
remained elevated as compared with controls. By contrast, 
in patients with early HIV infection (,1 year postinfection), 
the sCD163 levels at 3 months of treatment were similar to 
those of controls.123 All together, these studies suggest that 
early ART could result in the decreased activation of CD8 
T-cells and monocytes–macrophages, and they support the 
hypothesis that the activation of these cells could be reversed 
to normal levels with early ART.
Residual viral replication
Despite receiving effective ART, HIV patients may have 
residual viral replication below the detection limits of the 
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techniques commonly used, and/or they may have episodes 
of transient viral replication. It has been hypothesized that 
adding an additional antiretroviral drug could control this 
residual viral replication and reduce inflammation and 
immune activation, although the data are controversial. 
The results on the effect of ART intensification with mara-
viroc or raltegravir are contradictory, and the effect on the 
reduction of the inflammatory response, in any case, is 
modest.148–152
ART-dependent effects
Some antiretroviral drugs can induce endothelial dysfunc-
tion and oxidative stress and promote an inflammatory 
response. Drugs such as ritonavir, indinavir, lopinavir, 
zidovudine, and abacavir have been associated with these 
deleterious effects.42–45 It has been suggested that other anti-
retroviral drugs, such as raltegravir, may have an additional 
beneficial effect on these processes, independently of the 
suppression of viral replication. Some studies have shown 
that substituting a PI or non-nucleoside/nucleotide reverse 
transcriptase inhibitors with raltegravir reduces the levels 
of circulating inflammatory markers such as IL-6, hsCRP, 
or D-dimer.153–155
Coinfections
Chronic coinfections with HCV or herpes viruses, very com-
mon in the HIV population, might activate inflammatory and 
immunological mechanisms, although HIV viral replication 
is suppressed.
Bacterial translocation
HIV causes damage in the intestinal mucosa, favoring the 
translocation of bacterial products that stimulate immune 
activation.156–158 During acute infection phases, HIV severely 
damages the lymphoid tissue associated with the intestinal 
mucosa, with a massive depletion of T-cell lymphocytes. In 
patients with controlled chronic HIV infection, this lymphoid 
tissue cannot fully recover, and a predisposition to bacterial 
translocation persists in spite of ART.159,160
Established atherosclerosis
Atherosclerosis is, by itself, a process that is accompanied by 
persistent inflammation and immune activation.161 The devel-
opment of atherosclerotic lesions prior to the start of the sup-
pressive ART could be partially responsible for the persistent 
elevation of inflammation and immune activation biomarkers 
(intraplaque foam cells and endothelial  dysfunction). In this 
Residual HIV replication
Chronic coinfections
Bacterial translocation
Established vascular
damage
Homeostatic drive
Persistent inflammation
and immune activation
Antiretroviral drugs
Figure 2 Factors implicated in persistent inflammation and immune activation in HIV patients.
Notes: HIV-infected patients have a persistent state of inflammation and immune activation in spite of the suppression of HIV replication via ART. Various factors might 
be implicated: 1) homeostatic drive: after reaching an immune/inflammatory set point, the immunological and inflammatory response persist in spite of eliminating the initial 
stimulus; 2) residual nondetected HIV replication; 3) proinflammatory effects of certain antiretroviral drugs; 4) translocation of bacterial products through damaged intestinal 
mucosa; 5) coexistence of chronic HCV or herpes virus infection, common in the HIV population; and 6) established vascular lesions.
Abbreviations: HIV, human immunodeficiency syndrome; ART, antiretroviral therapy; HCV, hepatitis C virus.
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regard, the use of rosuvastatin in patients receiving ART has 
revealed reduced circulating levels of sCD14 and decreased 
CD14+/CD16+ monocytes, but it did not affect systemic 
inflammatory biomarkers.162,163
Conclusion
Patients with HIV infection are at increased cardiovascular 
risk due to the HIV infection itself, and due to other factors 
such as ART-associated metabolic abnormalities, lifestyle, or 
the coexistence of chronic infections. ART was initially pro-
posed as the causal factor for CVD in these patients; however, 
there is growing evidence supporting a net beneficial effect on 
CVD risk, presumably through the control of viral replication 
and the subsequent reduction of inflammation and immune 
activation. Nevertheless, in spite of optimal treatment, HIV 
patients maintain a state of persistent inflammation and 
immune activation that facilitates the development of CVD. 
In this regard, strategies to control these processes, in addition 
to ART and the treatment of traditional cardiovascular risk 
factors, may be useful in CVD prevention for HIV patients.
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